Wouldn't it be better for to spin out and partner Lympro instead of spin out and sell? The way I am looking at this is the partner, whomever it is, is already partnered with revenue generating asset. Also, because AMBS and its staff know the underlying data and function of Lympro. It would basically equate to an equity position where the partnering company is providing logistics in exchange for rollout and equity. I think that would be a better position for a company partnering with such a asset because we can assume that an equity position would be in play and it would be much easier to make their money back with an equity position in the term of royalties or just plain stock. I could be way far off, but that's how I look at it.